HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Adjusts Price Target To $6 (5-1 Reverse Stock Split)
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Sean Lee maintains a Buy rating on Monopar Therapeutics (NASDAQ:MNPR) and adjusts the price target to $6 from $2 following a 5-1 reverse stock split.
August 14, 2024 | 6:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Monopar Therapeutics and adjusts the price target to $6 from $2 following a 5-1 reverse stock split.
The maintenance of a Buy rating and the significant increase in the price target from $2 to $6 following a 5-1 reverse stock split is likely to positively impact investor sentiment and the stock price of Monopar Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100